Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.

The present study was designed to evaluate the bronchodilating role of zafirlukast, a CysLT(1)receptor antagonist, at the standard dosage currently recommended in the marketing of this agent in smokers with COPD. The study was performed using a double-blind, cross-over, randomized design and was conducted on 2 non-consecutive days. Sixteen outpatients suffering from stable COPD received 40 mg oral zafirlukast, or placebo. Lung function was controlled before drug administration and 30, 60, 120, 180, 240 min thereafter. At the end of the 4-h period, each patient received 400 microg inhaled salbutamol and spirometric testing was performed 30 min later. Zafirlukast, but not placebo, produced a significant (P<0.05) bronchodilation between 30 min and 4 h following administration, with a maximum mean increase in FEV(1)of 0.134 l (11.2%) above baseline after 2 h. Nine of 16 patients showed an increase in FEV(1)of at least 15% above baseline after zafirlukast. The maximum mean increase in FEV(1)after zafirlukast in these subjects, who were considered responders, observed after 2 h, was 0.221 (19.4%). The mean difference of post-salbutamol FEV(1)values after zafirlukast and placebo (-0.036 l) was not significant (P<0.05). In responders, the mean of differences in pre- and post-salbutamol FEV(1)values after zafirlukast was 0.077 l, whereas the mean of differences between post-salbutamol values after zafirlukast and those after placebo was -0.064 l. The mean AUC(0-4 h)for all patients was 0.121 l for placebo and 0.385 l for zafirlukast. The difference between the placebo and zafirlukast AUC(0-4 h)was significant (P<0.05). The individual FEV(1)AUC(0-4 h)after zafirlukast were higher than those after placebo in 12 out of 16 patients. These findings suggest that cysteinyl leukotrienes might be one of the causes of persistent bronchoconstriction in COPD, at least in several smokers, but do not confirm the hypothesis that the effects of zafirlukast and salbutamol are independent and additive.

Laboratory survival, growth, and digestive gland histologic features of squids reared on living and non-living fish diets.

The effects of non-living diets on the survival, growth, and digestive gland histologic features of the bigfin reef squid (Sepioteuthis lessoniana Lesson, 1830) cultured in the laboratory were evaluated during one-half of their life cycle (95 days). Two groups of squids (n = 16 per group) were held in closed seawater systems with similar water volume, temperature, salinity, water filtration, and water flow velocities. Food for the control group consisted of live, freely swimming fish (Cyprinodon variagatus); the test group was trained to grab freshly dead fish (days 1 to 45) and then thawed, frozen fish (days 46 to 95). The two groups were evaluated for differences in (1) food intake, (2) survival, (3) growth (wet weight, mantle length, instantaneous growth rate), (4) morphologic (mantle thickness in four locations, digestive gland weight), and (5) digestive gland histologic features (indices for nuclear density and relative vacuolar density). Unexpectedly, no significant differences were found between the two groups. Mean wet weight increased from 32.1 g to 342.9 g for the control group and from 58.6 g to 372.0 g for the group fed dead food. The results demonstrate that laboratory-cultured squids can survive and grow when fed dead fish (fresh or frozen) as well as live fish without adverse effects on growth, survival, or digestive gland histologic features.

Alternative diets for maintaining and rearing cephalopods in captivity.

The requirement of live marine prey for cephalopod mariculture has restricted its practicality for inland research laboratories, commercial enterprises and home aquarists. We evaluated acceptability and resultant growth on: (a) frozen marine shrimps, (b) live and frozen marine polychaete worms, (c) live and frozen marine crabs, (d) frozen marine fishes, (e) live adult brine shrimp, (f) live freshwater fish and (g) live freshwater crayfish. The diets were presented for periods of 2 to 11 weeks to octopuses, cuttlefishes or squids and in most trials the results were compared to animals fed control diets of live marine shrimps, crabs or fish. Overall, frozen marine shrimp proved to be the best alternative diet tested. Adult Octopus maya on frozen marine shrimp diets grew as well as those on control diets at 2.8% body weight per day (%/d) compared to 2.0%/d on live freshwater crayfish, 1.4%/d on live marine polychaete worms and 0.8%/d on live freshwater fish (Tilapia sp.). Juvenile Octopus maya and Octopus bimaculoides also grew comparably to controls when fed frozen marine shrimps; growth rates ranged from near 3.0%/d at 3 months of age to nearly 2.5%/d at 6 months of age. Thus, these alternatives are acceptable as the octopuses end their exponential growth phase at an age of 3 - 5 months. Attempts to rear O. maya hatchlings and juveniles (up to 1 month of age) on dead foods resulted in high mortality and slow or negative growth. No live or dead alternative diet has been found yet that will promote good growth and survival in hatchling octopuses. Hatchling F3 generation Sepia officinalis (the European cuttlefish) were reared for 6 weeks exclusively on adult brine shrimp (Artemia salina).(ABSTRACT TRUNCATED AT 250 WORDS)